| NewAmsterdam Pharma | Phase 3 | $4.7B | Cardiovascular Disease, Dyslipidemia |
| NewAmsterdam Pharma Company | Phase 3 | $3.8B | Cardiovascular Disease, Metabolic Disease |
| enGene | Phase 2/3 | $110.5M | Oncology, Urology |
| Kynexis | phase-2 | — | Neuroscience, Psychiatry |
| Pheon Therapeutics | preclinical | — | Oncology |
| Altesa BioSciences | Phase 2 | — | Respiratory, Infectious Disease |
| Inversago Pharma | phase-2 | — | Metabolic |
| Granite Bio | Phase 1 | — | Inflammation, Autoimmunity |
| Rectify Pharmaceuticals | Pre-clinical | — | Hepatobiliary, Cardio-Renal-Metabolic |
| Sparrow Pharmaceuticals | Phase 2 | — | Type 2 Diabetes, Cardiometabolic Diseases |
| Verdiva Bio | Phase 2 | — | Obesity, Cardiometabolic Disorders |
| Navigator Medicines | Phase 2 | — | Inflammatory Disorders, Autoimmune Diseases |
| Tessellate BIO | Pre-clinical | — | Oncology |
| ISA Pharmaceuticals | Phase 2 | — | Oncology, Infectious Diseases |
| Allecra Therapeutics | Phase 3 | — | Infectious Disease |
| Elevara Medicines | Phase 2 | — | Rheumatoid Arthritis, Chronic Inflammatory Diseases |
| Azafaros | Phase 3 | — | Lysosomal Storage Disorders, Rare Metabolic Diseases |
| F2G | Phase 3 | — | Infectious Disease, Rare Diseases |
| Engrail Therapeutics | Phase 1 | — | Neurologic Disorders, Neuropsychiatric Disorders |
| Enterprise Therapeutics | Phase 1 | — | Cystic Fibrosis, Asthma |
| AIRNA | Pre-clinical | — | Oncology, Rare Diseases |
| IDRx, Inc. | phase-1 | — | Oncology |
| VectorY Therapeutics | preclinical | — | Neuroscience |
| Aiolos Bio | phase-2 | — | Respiratory, Immunology |